期刊
BIOMEDICINES
卷 11, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines11061553
关键词
vedolizumab; trough levels; loss of response; subsequent therapy; therapeutic drug monitoring
This retrospective study found that vedolizumab trough levels do not predict response to subsequent medical therapy in patients with inflammatory bowel disease. However, lower drug levels may indicate a more severe disease pattern and potential need for surgery in the future.
Background: Vedolizumab trough serum levels have been associated with clinical and endoscopic response in patients with inflammatory bowel disease (IBD). A recent study demonstrated that higher trough levels before dose escalation are associated with favorable outcomes. Objectives: We aimed to identify whether vedolizumab trough levels predict outcome of subsequent therapy. Methods: This retrospective study included IBD patients consecutively receiving vedolizumab therapy between November 2014 and June 2021. Only patients with a loss of response (LOR) to vedolizumab and available trough drug levels prior to therapy cessation were included. Clinical and endoscopic scores were recorded at 6 and 12 months post switching therapy. Results: Overall, 86 IBD patients (51 Crohn's disease, 35 ulcerative colitis) who discontinued vedolizumab were included; of those, 72 (83.7%) were due to LOR. Upon vedolizumab discontinuation, 66.3% of patients were switched to another biologic therapy. Trough vedolizumab levels at discontinuation due to LOR did not differ between patients with clinical response and LOR regarding subsequent therapy at 6 months [median 33.8 & mu;g/mL (IQR 13.2-51.6) versus 31.7 & mu;g/mL (IQR 9.1-64.8), p = 0.9] and at 12 months [median 29.6 & mu;g/mL (IQR 14.3-51.6) versus 34.1 & mu;g/mL (IQR 12.2-64.7), p = 0.6]. Patients progressing to subsequent surgery had numerically lower vedolizumab trough levels at LOR compared with patients who were treated with an additional medical therapy (median 14.3, IQR 4-28.2 & mu;g/mL versus 33.5, IQR 13-51.6 & mu;g/mL, p = 0.08). Conclusions: Vedolizumab trough levels upon LOR do not predict response to subsequent medical therapy; however, lower drug levels may suggest a more aggressive disease pattern and future need for surgery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据